First, a definition: Drugs like Ozempic and Wegovy are glucagon-like peptide-1 receptor agonists (commonly referred to as GLP-1s) and drugs like Zepbound and Mounjaro are glucose-dependent insulinotropic polypeptides (GIP)
The methodology included: Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America Product mapping across short-acting GLP-1 agonists, long-acting GLP-1 agonists, dual-action therapies (GLP-1/GIP), and emerging tri-agonist candidates Analysis of reported and modeled annual revenues specific to GLP-1 drug portfolios Coverage of manufacturers representing 75-80% of global market share in 2024 Extrapolation using bottom-up (prescription volume ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across drug type (short-acting, long-acting, dual-action), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), indication (type 2 diabetes, obesity, cardiovascular diseases), and administration route (subcutaneous injection, oral, inhalation) Download Free Sample Kindly complete the form below to receive a free sample of this Report This is really good guys
If a GLP-1 is not available or not affordable for you, there are still many other effective tools for improving your diabetes control and weight
This study describes the crystal structure of the human GLP-1R ECD in complex with Fab 3F52 and reveals the molecular details of antagonism and receptor specificity of Fab 3F52
/assets/images/provider/photos/2826746.png)
